Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.38 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001716 | 0.83 | PTPRZ1 (0.61) | PTPRZ1LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL7050691 | 0.81 | PTPRZ1 (0.59) | PTPRZ1LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL10181461 | 0.79 | PTPRZ1 (0.58) | PTPRZ1LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL718482 | 0.79 | PTPRZ1 (0.58) | PTPRZ1LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL1145752 | 0.79 | PTPRZ1 (0.58) | PTPRZ1LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL25467365 | 0.79 | PTPRZ1 (0.58) | PTPRZ1LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL7051745 | 0.79 | PTPRZ1 (0.58) | PTPRZ1LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL2199349 | 0.79 | ALDH1A1 (0.41) | PTPRZ1LMNAMAPK1HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1857101 | 0.78 | CA2 (0.59) | PTPRZ1LMNAMAPK1HTTSMN1; SMN2 | |
| SCHEMBL6001722 | 0.78 | PTPRZ1 (0.71) | PTPRZ1LMNAMAPK1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694874-A2 | GPX4 INHIBITORS AND SENOLYTIC COMPOUNDS AND USES THEREOF | Rubedo Life Sciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260007689-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | RUBEDO LIFE SCIENCES INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12485132-B2 | GPX4 inhibitors and senolytic compounds and uses thereof | Rubedo Life Sciences, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250319109-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | RUBEDO LIFE SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20240408124-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | Rubedo Life Sciences, Inc. | 2024-12-12 | — | — | US | disclosed |
| WO-2024249613-A2 | GPX4 INHIBITORS AND SENOLYTIC COMPOUNDS AND USES THEREOF | Rubedo Life Sciences, Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| WO-2007134107-A2 | COLD MENTHOL RECEPTOR-1 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
| EP-1761529-B1 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007068418-A1 | USE OF PYRROLO [2 , 3-B] PYRIDINES TO PREPARE A MEDICAMENT FOR TREATING PAIN | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| EP-1761529-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005123731-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | NOVARTIS AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1480957-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074495-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
| US-5247042-A | ISOTROPIC ACRYLIC POLYMER EXHIBITING NONLINEAR OPTICAL RESPONSE | HOECHST CELANESE CORP. | 1993-09-21 | — | — | US | disclosed |
| WO-1991003504-A1 | ACRYLIC POLYMERS EXHIBITING NONLINEAR OPTICAL RESPONSE | HOECHST CELANESE CORPORATION (US) | 1991-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007689-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | GPX4, GPX1, PRDX4 | PTPRZ1 2077/4885LMNA 1722/4885MAPK1 3428/4885 |
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | PTPRZ1 2842/4885LMNA 3670/4885MAPK1 1209/4885 |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | PTPRZ1 2248/4885LMNA 1449/4885MAPK1 1174/4885 |
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | PTPRZ1 994/4885LMNA 2907/4885MAPK1 2346/4885 |
| US-20250319109-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | GPX4, GPX1, PRDX3 | PTPRZ1 1918/4885LMNA 2339/4885MAPK1 3051/4885 |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | PTPRZ1 4040/4885LMNA 1142/4885MAPK1 3904/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | PTPRZ1 4094/4885LMNA 3406/4885MAPK1 2494/4885 |
| US-20240408124-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | GPX4, GPX1, PRDX3 | PTPRZ1 1918/4885LMNA 2339/4885MAPK1 3051/4885 |
| US-12485132-B2 | GPX4 inhibitors and senolytic compounds and uses thereof | GPX4, GPX1, PRDX3 | PTPRZ1 1918/4885LMNA 2339/4885MAPK1 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.